CONSOLIDATED FINANCIAL STATEMENTS OF LUNDBECKFONDEN
LUNDBECKFONDEN ANNUAL REPORT 2018
93
36. Group overview - continued Company name
Country
Ownership
Lundbeck SAS
France
100%
Lundbeck İlaç Ticaret Limited Şirketi
Sofipharm SA, including
France
100%
Lundbeck Group Ltd. (Holding), including
- Laboratoire Elaiapharm SA
France
100%
- Lundbeck Limited
United Kingdom
100%
Germany
100%
- Lundbeck Pharmaceuticals Ltd.
United Kingdom
100%
Greece
100%
- Lifehealth Limited, including
United Kingdom
100%
Hong Kong
100%
- Lundbeck UK LLP (2)
United Kingdom
100%
Hungary
100%
Lundbeck USA Holding LLC, including
United States
100%
India
100%
- Lundbeck LLC, including
United States
100%
Ireland
100%
- Chelsea Therapeutics International, Ltd., including
United States
100%
Israel
100%
- Lundbeck NA Ltd
United States
100%
Lundbeck Italia S.p.A.
Italy
100%
- Lundbeck Pharmaceuticals, LLC
United States
100%
Lundbeck Pharmaceuticals, Italy S.p.A., including
Italy
100%
- Lundbeck Research USA, Inc.
United States
100%
Luxembourg
100%
Lundbeck de Venezuela, C.A.
Venezuela
100%
Japan
100%
Republic of Korea
100%
Subsidiaries of ALK-Abelló A/S
Latvia
100%
ALK-Abelló Nordic A/S
Denmark
100%
UAB Lundbeck Lietuva
Lithuania
100%
Denmark
100%
Lundbeck Malaysia SDN. BHD.
ALK e-com A/S
Malaysia
100%
ALK-Abelló Ltd.
United Kingdom
100%
Mexico
100%
France
100%
Lundbeck B.V.
ALK-Abelló S.A.
Netherlands
100%
Germany
100%
Prexton Therapeutics B.V., including
ALK-Abelló Arzneimittel GmbH
Netherlands
100%
Austria
100%
- Prexton Therapeutics S.A
ALK-Abelló Allergie-Service GmbH
Switzerland
100%
ALK-Abelló AG
Switzerland
100%
New Zealand
100%
Switzerland
100%
H. Lundbeck AS
ALK AG (in liquidation)
Norway
100%
Turkey
100%
Lundbeck Pakistan (Private) Limited
ALK ilaç ve Alerji Ürünleri Ticaret Anonim Şirketi
Pakistan
100%
Netherlands
100%
Lundbeck America Central S.A.
ALK-Abelló B.V.
Panama
100%
ALK-Abelló S.A.
Spain
100%
Peru
100%
ALK-Abelló S.p.A.
Italy
100%
Philippines
100%
Poland
100%
Lundbeck Business Service Centre Sp.z.o.o.
ALK-Abelló sp. z.o.o.
Poland
100%
United States
100%
Lundbeck Poland Sp.z.o.o.
ALK-Abelló, Inc.
Poland
100%
ALK-Abelló, Source Materials, Inc.
United States
100%
OKC Allergy Suppliers Inc.
United States
100%
OKC Crystal Laboratory Inc.
United States
100%
Canada
100%
China
100%
Slovakia
100%
Falck Pty. Ltd.
Australia
55%
Falck (Victoria) Pty. Ltd.
Australia
55%
Belgium
49%
Lundbeck GmbH Lundbeck Hellas S.A. Lundbeck HK Limited Lundbeck Hungária KFT Lundbeck India Private Limited Lundbeck (Ireland) Ltd. Lundbeck Israel Ltd.
- Archid S.a. Lundbeck Japan K. K. Lundbeck Korea Co., Ltd. SIA Lundbeck Latvia
Lundbeck México, SA de CV
Lundbeck New Zealand Limited
Lundbeck Peru S.A.C. Lundbeck Philippines Inc.
Lundbeck Portugal - Produtos Farmacêuticos Unipessoal Lda
Portugal
100%
Lundbeck Romania SRL
Romania
100%
Russia
100%
Singapore
100%
Slovakia
100%
Lundbeck RUS OOO Lundbeck Singapore PTE. LTD. Lundbeck Slovensko s.r.o. Lundbeck Pharma d.o.o.
Slovenia
100%
Lundbeck South Africa (Pty) Limited, including
South Africa
100%
- H. Lundbeck (Proprietary) Limited
South Africa
100%
Spain
100%
Sweden
100%
Switzerland
100%
Lundbeck España S.A. H. Lundbeck AB Lundbeck (Schweiz) AG
Company name
ALK-Abelló Pharmaceuticals, Inc. ALK Medical Consulting Services Company Limited ALK Slovakia s.r.o.
Country
Ownership
Turkey
100%
United Kingdom
100%
Subsidiaries of Falck A/S Ambulance
Falck Benelux NV